Viemed Healthcare (NASDAQ:VMD) Announces Earnings Results, Misses Expectations By $0.05 EPS

Viemed Healthcare (NASDAQ:VMD) issued its quarterly earnings results on Monday. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.05), FiscalAI reports. The company had revenue of $78.10 million for the quarter, compared to analyst estimates of $78.00 million. Viemed Healthcare had a return on equity of 10.52% and a net margin of 5.20%.

Viemed Healthcare Stock Performance

Shares of VMD stock opened at $11.69 on Tuesday. Viemed Healthcare has a 52 week low of $5.96 and a 52 week high of $12.61. The company has a market cap of $448.19 million, a PE ratio of 31.59 and a beta of 1.10. The company has a current ratio of 1.22, a quick ratio of 1.10 and a debt-to-equity ratio of 0.06. The company’s fifty day simple moving average is $11.16 and its 200-day simple moving average is $9.70.

Insider Activity

In other Viemed Healthcare news, insider William Frazier sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $11.72, for a total transaction of $117,200.00. Following the transaction, the insider owned 73,214 shares in the company, valued at $858,068.08. The trade was a 12.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Timothy Smokoff sold 20,000 shares of the company’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $11.50, for a total value of $230,000.00. Following the completion of the sale, the director directly owned 75,518 shares of the company’s stock, valued at $868,457. The trade was a 20.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 20.60% of the company’s stock.

Hedge Funds Weigh In On Viemed Healthcare

A number of institutional investors have recently added to or reduced their stakes in VMD. Kemnay Advisory Services Inc. acquired a new stake in shares of Viemed Healthcare during the fourth quarter valued at about $46,000. Quarry LP acquired a new position in shares of Viemed Healthcare in the third quarter worth about $48,000. AQR Capital Management LLC acquired a new position in shares of Viemed Healthcare in the first quarter worth about $90,000. Invesco Ltd. boosted its holdings in Viemed Healthcare by 25.5% in the second quarter. Invesco Ltd. now owns 18,652 shares of the company’s stock valued at $129,000 after purchasing an additional 3,795 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its holdings in Viemed Healthcare by 52.7% in the fourth quarter. MetLife Investment Management LLC now owns 18,565 shares of the company’s stock valued at $138,000 after purchasing an additional 6,408 shares during the last quarter. Institutional investors and hedge funds own 74.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “hold (c+)” rating on shares of Viemed Healthcare in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat, Viemed Healthcare presently has a consensus rating of “Hold”.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.